Search Videos and More
News
Making Breakthroughs in ALL From Youth to Adulthood
When Ann Carroll was diagnosed with cancer at age 28, her dream to get married and have a baby felt out of reach. Now, seven years later and cancer-free, she is living that dream with her husband and their 7-month-old son, Teddy.
News
Cell-Death Safety Net a Potential New Cancer Target
In the rare event that an elevator cable breaks, modern buildings have additional fail-safe mechanisms. For example, counterweight and mechanical brakes prevent the car from plummeting to the ground.
News
Dana-Farber Launches Colorectal Cancer Screening Program in Central Asia
Dana-Farber Cancer Institute's Center for Global Health launched the first colorectal cancer screening program in Central Asia this week, partnering with Uzbekistan’s Ministry of Health and National Cancer Center to pilot a sustainable, early detection model that could be scaled across the region.
News
Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma
Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients
News
Dana-Farber’s Largest Single Gift Advances Planned Cancer Hospital for New England
Dana-Farber Cancer Institute today announced the largest single gift in its history through a new joint commitment from Josh and Anita Bekenstein and the Jonathan and Jeannie Lavine family. The transformational gift for the future cancer hospital builds on the two families’ decades-long dedication to Dana-Farber’s mission of delivering expert, compassionate patient care while accelerating discoveries that improve outcomes for people with cancer around the world.
News
Three Dana-Farber Cancer Institute scientific leaders elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026
Dr. Alice Shaw, Dr. Kimberly Stegmaier and Dr. Matthew Vander Heiden have been elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026.
News
Taming Chronic Inflammation
Dana-Farber researchers explore how lifestyle choices may help reduce cancer risk and improve outcomes
News
Dana-Farber Research News 02.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
News
Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows
The addition of a CDK 4/6 inhibitor to standard therapy in patients with “double-positive” metastatic breast cancer significantly extended the time the disease did not progress according to data published today in the New England Journal of Medicine.
News
Ten Cancer-Related Breakthroughs Giving Us Hope in 2026
Cancer treatment has evolved dramatically in the first quarter of this century, but there is still much more to do to improve the lives of people with cancer.
News
More Than 145 Dana-Farber Affiliated Faculty Named as 2026 Top Doctors™ in Boston Magazine
Boston magazine has named more than 145 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the Boston magazine Top Doctors™ list draws from hundreds of Boston-area physicians in many medical specialties
News
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer
In patients with advanced triple negative breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab led to durable responses and improved progression free survival compared to the current standard treatment, according to results of the ASCENT-04/KEYNOTE-D19 study, published today in the New England Journal of Medicine.